Skip to main content
Ajjai S. Alva on Muck Rack

Ajjai S. Alva

As seen in: Nature, Wiley, Science Magazine, European Urology, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ajjai S.

Contact Ajjai S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

|
By Minas P. Economides, Peter O’Donnell Verified, Ajjai S. Alva, Matthew I. Milowsky, Marisa Kollmeier, Scot A. Niglio, Jesse B. Persily, Randy F. Sweis, Tracy Rose, Gopakumar V. Iyer, Daniel E. Spratt, Phillip L. Palmbos, Judith D Goldberg, Tsivia Hochman, Kaitlyn Francese
| European Urology Verified
What does this study add? This study demonstrates that incorporating pembrolizumab into trimodality bladder-preservation therapy is feasible and can achieve high pathologic complete response rates, suggesting meaningful antitumor activity. Importantly, while the 2-yr bladder-intact disease-free survival did not surpass the predefined threshold, durable metastasis-free and overall survival outcomes were observed.
Open in Who Shared Issue with article?

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | Journal of Clinical Oncology

|
By Ajjai S. Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi
| ascopubs.org
Ajjai S. Alva, MD1; Pam K. Mangat, MS2; Elizabeth Garrett-Mayer, PhD2; Susan Halabi, PhD3; Damien Hansra, MD4; Carmen J. Calfa, MD5; Maged F. Khalil, MD6; Eugene R. Ahn, MD7; Timothy L. Cannon, MD8; Pamela Crilley, DO9; Julie G. Fisher, MD10; Derrick S. Haslem, MD11; Sagun Shrestha, MD12; Kaitlyn R. Antonelli, BA2; Nicole L. Butler, MPH2; Sasha L. Warren, MS2; Andrew L. Rygiel, MPH2; Shamika Ranasinghe, MS2; Suanna S. Bruinooge, MPH2; and Richard L.
Open in Who Shared Issue with article?

The Final Results of KEYNOTE-361 - Ajjai Alva

|
By Ajjai S. Alva
| UroToday Verified
Read the Full Video Transcript Alicia Morgans:Hi, my name is Alicia Morgans and I'm a GU medical oncologist at Northwestern University, where I'm also an Associate Professor of Medicine. I am so excited to have here with me today, Dr. Ajjai Alva, who is a GU medical oncologist and Associate Professor of Medicine at the University of Michigan. Thank you so much for being here with me today, Dr. Alva. Ajjai Alva: It's a real pleasure to be here, Alicia. Thanks for having me. Alicia Morgans: Wonderful.
Open in Who Shared Issue with article?
See all 5 articles